China Biologic Products Holdings, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
China Biologic Products Holdings, Inc. - overview
Established
2002
Location
Beijing, -, China
Primary Industry
Pharmaceuticals
About
Established in 2002 and based in Beijing, China, China Biologic Products Holdings, Inc. operates as a biopharmaceutical company that develops and manufactures plasma-based pharmaceutical products used for the prevention of diseases such as measles and hepatitis. In 2016, China Biologic Products Holdings, Inc. acquired full ownership of Guizhou Taibang.
In 2021, the company was delisted from Nasdaq. As of 2022, the company's chairman and CEO is Joseph Chow, who has served as the core executive of many well-known listed or non-listed companies. The company has production bases located in Shandong and Guizhou. The business of the company includes the R&D, manufacture, and sales of plasma-based biopharmaceutical products to hospitals and other healthcare facilities.
It has a product line of more than 20 grades of blood products. Its products include human albumin, human immunoglobulin (pH4) for intravenous injection, human fibrinogen, epidemic diseases, immune system disorders, antibody deficiencies and coagulopathy.
Current Investors
GIC, Abu Dhabi Investment Authority, China Life Capital
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Medical Devices & Equipment, Pharmaceutical Research & Development
Website
www.chinabiologic.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
China Biologic Products Holdings, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | Completed | China Biologic Products Holdings, Inc. | - | ||||||||
| LP Direct | Completed | China Biologic Products Holdings, Inc. | - | ||||||||
| Public to Private | Completed | China Biologic Products Holdings, Inc. | - | ||||||||
| PIPE | Completed | China Biologic Products Holdings, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | China Biologic Products Holdings, Inc. | - |
Displaying 1 - 5 of 16
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.